Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Key Inclusion Criteria:

All Participants - Participants meeting all the following criteria were considered for enrollment:

1. The participant had a life expectancy of > 6 months.
2. The participant had an Eastern Cooperative Oncology Group performance status of 0-2.

3. The participant had adequate baseline organ function, including cardiac, renal, and hepatic function:

   • Left ventricular ejection fraction 2: institutional lower limit of normal as measured by multigated acquisition scan or 2-dimensional echocardiogram within 28 days prior to the start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram.
   • Serum creatinine ≤ 1.5 milligrams/deciliter (dL).
   • Serum albumin ≥ 3.2 grams (g)/dL (or 32 g/liter [L]) in the absence of receipt of intravenous albumin within the previous 72 hours.
   • Aspartate transaminase and alanine transaminase ≤ 2.5 times the upper limit of normal (ULN).
   • Creatine phosphokinase ≤ 2.5 times the ULN.
   • Absolute neutrophil count ≥ 0.5×10\^9/L.
4. If a woman of child-bearing potential, the participant had a negative serum or urine pregnancy test within 1 week prior to tagraxofusp treatment (intervals shorter than 1 week are acceptable, if required by institutional guidelines).
5. The participant (either male or female) agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 1 week after the last tagraxofusp infusion.
6. The participant can adhere to the study visit schedule and other protocol requirements, including follow-up for response assessments.

Myelofibrosis (Stage 2) - Participants with MF meeting all of the following criteria, in addition to those specified for all participants, above, are eligible for enrollment in Stage 2:

1. Participant meets the 2016 World Health Organization (WHO) diagnostic criteria for MF and has an International Prognostic Scoring System/Dynamic International Prognostic Scoring System (IPSS/DIPSS)/DIPSS-plus intermediate-2 or high-risk disease. Participants with IPSS/DIPSS/DIPSS-plus low or intermediate-1 risk disease who have at least 1 of the following symptoms are also eligible: MF-related anemia (hemoglobin \< 10 g/dL), splenomegaly (palpable size > 10 centimeters), leukocytosis (white blood cell count [WBC] > 25×10\^9/L), marked thrombocytosis (platelet count > 1,000×10\^9/L), or constitutional symptoms (weight loss > 10%, during prior 6 months or fever [> 37.5 degrees Celsius or drenching night sweats for > 6 weeks]), as recommended by the European LeukemiaNet/International Working Group (ELN/IWG) 2018 criteria.
2. Participant was approved JAK therapy (JAK1/JAK2 or JAK2) resistant/refractory or intolerant, in accordance with the ELN/IWG 2018 criteria, and at least 4 weeks have elapsed between the last dose of any MF-directed drug treatments, excluding HU, and study enrollment (first dose). HU can be continued until 2 weeks prior to study enrollment.

3. Participant was not eligible for an immediate allogeneic-stem cell transplantation.

   CMML (Stage 3A):

4. Participant had a 2016 WHO-defined diagnosis of CMML (persistent monocytosis ≥ 1×10\^9/L for at least 3 months, with other causes excluded, and monocytes ≥10% of WBC in peripheral blood, no criteria and no previous history of CMML, essential thrombocythemia, polycythemia vera, and acute promyelocytic leukemia; if eosinophilic, neither platelet-derived growth factor receptor A, platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1 rearrangements nor pericentriolar material 1-JAK2 translocation; \< 20% blasts in peripheral blood and bone marrow aspirate; > 1 following criteria: dysplasia in > 1 myeloid lineage, acquired clonal cytogenetic or molecular abnormality in hematopoietic cells).
5. Participant had 2016 WHO-defined CMML-1 (2-4% blasts in peripheral blood and/or 5-9% blasts in bone marrow) and CMML-2 (5-19% blasts in peripheral blood and/or 10-19% blasts in bone marrow, and/or presence of Auer rods).

6. Participant was refractory/resistant/intolerant, as defined for the purposes of this study (in the absence of a standard definition for CMML) below, to HMAs, HU, or intensive chemotherapy, including:

   • Resistance/intolerance to HU is defined as:

     • Uncontrolled myeloproliferation, (platelets > 400×10\^9/L and WBC > 10×10\^9/L after 3 months of at least 2 g/day of HU); or
     • Myelosuppression at a clinically relevant dose; or
     • Presence of unacceptable HU-related non-hematological toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis, or fever at any dose of HU.

   • Conventional definition for HMA failure is defined for the purposes of this study (in the absence of a standard definition for CMML) as:

     • Disease progression following at least 4 to 6 cycles of 5-azacitidine or decitabine; or
     • Relapse after achieving response; or
     • Intolerance to 5-azacitidine or decitabine at the prescribed dose.

   or

   • Participant was classified as high-risk based on the presence of morphological features, as described by the 2016 WHO prognostic system, and the clinical and molecular features described in molecularly integrated prognostic systems, such as the Groupe Français des Myélodysplasies, Mayo Molecular Model, and the CMML specific prognostic model and thus is not expected to benefit from HMAs.
7. Participant was ineligible for an immediate allogeneic stem cell transplantation (allo-SCT).

Key Exclusion Criteria:

1. Participant had persistent clinically significant toxicities Grade ≥2 from previous therapies, including cytotoxic chemotherapy, targeted therapies, biological therapies, or immunotherapies, not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue).
2. Participant received treatment with any disease-related therapy, including radiation therapy within 14 days of study entry.
3. Participant received an allo-SCT within 3 months of study entry.
4. Participant received treatment with another investigational agent within 14 days of study entry or concurrent treatment with another investigational agent.
5. Participant previously received treatment with tagraxofusp or has a known hypersensitivity to any components of the drug product.
6. Participant had an active malignancy and/or cancer history (excluding myeloproliferative disorders and concomitant myeloid malignancies as specified in the inclusion criteria) that could confound the assessment of the study endpoints.
7. Participant had clinically significant cardiovascular disease (for example, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
8. Participant had uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would have put the participant at significant risk for pulmonary complications during the study.
9. Participant had known active or suspected disease involvement of the central nervous system (CNS). If suspected due to clinical findings, CNS disease was to be ruled out with relevant imaging and/or examination of cerebrospinal fluid.

Note: Other inclusion/exclusion criteria may apply.